Research map: Subphenotypes of Sickle Cell Disease: A Guide to Targeting Treatment?

Back to the article

Papers in this map

  1. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease · Kenneth I. Ataga · 2016 · 911 citations · Cited by this paper
  2. Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management · 2026 · Related
  3. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes · Gregory James Kato · 2006 · 869 citations · Cited by this paper
  4. Treatment Patterns and Clinical Outcomes After Immunotherapy Failure in Patients With Natural Killer/T‐Cell Lymphoma · 2026 · Related
  5. Intravascular hemolysis and the pathophysiology of sickle cell disease · Gregory James Kato · 2017 · 753 citations · Cited by this paper
  6. Dasatinib Exposure and Risk of CMV Reactivation in Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia · 2026 · Related
  7. Sickle Cell Hemoglobin Polymerization · W.A. Eaton · 1990 · 635 citations · Cited by this paper
  8. Intensive Induction in AML in the Era of Venetoclax: A Standing Count for “7 + 3”? · 2026 · Related
  9. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease · Elliott P. Vichinsky · 2019 · 623 citations · Cited by this paper
  10. ICC / WHO ‐Defined and NGS ‐Annotated Idiopathic Hypereosinophilia ( iHES / iHE ): Mutations, Clinical and Treatment Details, and Predictors of Survival · 2026 · Related
  11. Exagamglogene Autotemcel for Severe Sickle Cell Disease · Haydar Frangoul · 2024 · 472 citations · Cited by this paper
  12. Promoter TERT ‐ Related Hematopoietic Somatic Mosaicism in Patients With Telomere Biology Disorders · 2026 · Related
  13. Genetic modifiers of sickle cell disease · Martin H. Steinberg · 2012 · 318 citations · Cited by this paper
  14. Mosaic Chromosomal Alterations Identify Ultra‐High Risk Clonal Hematopoiesis in Patients With Lymphoma Undergoing Intensive Chemotherapy · 2026 · Related
  15. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso‐occlusive crises in patients with sickle cell disease: a phase III randomized, placebo‐controlled, double‐blind study of the gardos channel blocker senicapoc (ICA‐17043) · Kenneth I. Ataga · 2011 · 230 citations · Cited by this paper
  16. A New Fetal Hemoglobin‐Related Phenotype in Sickle Cell Anemia · 2026 · Related
  17. Chronic Hyper-Hemolysis in Sickle Cell Anemia: Association of Vascular Complications and Mortality with Less Frequent Vasoocclusive Pain · James G. Taylor · 2008 · 183 citations · Cited by this paper
  18. p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53 ‐Mutated Cases · 2026 · Related
  19. Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene · MH Steinberg · 1986 · 173 citations · Cited by this paper
  20. Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma · 2026 · Related
  21. Erythroid DAMPs drive inflammation in SCD · Mark T. Gladwin · 2014 · 112 citations · Cited by this paper
  22. Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial · Miguel Raul Abboud · 2025 · 29 citations · Cited by this paper
  23. Case series of patients with severe sickle cell disease treated with voxelotor (GBT440) by compassionate access · Gershwin Theophilus Blyden · 2018 · 25 citations · Cited by this paper
  24. Haemoglobin response to senicapoc in patients with sickle cell disease: a re‐analysis of the Phase III trial · Kenneth I. Ataga · 2021 · 23 citations · Cited by this paper
  25. An integrated therapeutic approach to sickle cell disease management beyond infancy · Jean‐Antoine Ribeil · 2023 · 13 citations · Cited by this paper

Source: OpenAlex (CC0)